Guk-Hee Suh

Guk-Hee Suh

Auto-generated profile, based on publicly available information

Guk-Hee Suh

Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 18450, Gyeonggi, Republic of Korea

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
YCYoung Min Choe
Young Min Choe
BLBoung Chul Lee
Boung Chul Lee
ICIhn-Geun Choi
Ihn-Geun Choi
GSGuk-Hee Suh
Guk-Hee Suh
DLDong Young Lee
Dong Young Lee
JKJee Wook Kim
Jee Wook Kim
Purpose: This study was performed to examine the usefulness of subscores on the Mini-Mental State Examination (MMSE) for predicting the progression of Alzheimer’s disease (AD) dementia in individuals with mild cognitive impairment (MCI). Patients and Methods: A total of 306 MCI individuals in the Alzheimer’s Disease Neuroimaging Initiative database were included in the study. Standardized clinical and neuropsychological tests were performed at baseline and at 2-year follow-up. Logistic regression analysis was conducted to examine the MMSE total and subscale scores to predict progression to AD dementia in MCI individuals. Results: The MMSE total score and the MMSE memory, orientation, and construction subscores were inversely associated with AD progression after controlling for all potential confounders; MMSE attention and language subscores were not correlated with AD progression. The MMSE delayed recall score among the MMSE memory subscores and the MMSE time score among the orientation subscores, especially week and day, were inversely associated with AD progression; the MMSE immediate recall and place scores were not correlated with progression. Conclusion: Our findings suggest that the MMSE memory, orientation, and construction subscores, which are simple and readily available clinical measures, could provide useful information to predict AD dementia progression in MCI individuals in practical clinical settings.

1 July 2006 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
GSGuk-Hee Suh
Guk-Hee Suh
AGAndrew J. Greenspan
Andrew J. Greenspan
SCSung-Ku Choi
Sung-Ku Choi

21 July 2006 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
GSGuk‐Hee Suh
Guk‐Hee Suh
MKMartin Knapp
Martin Knapp
CKCheol‐Joong Kang
Cheol‐Joong Kang

1 December 2005 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Closed access
GSGuk-Hee Suh
Guk-Hee Suh
HJHee Yeon Jung
Hee Yeon Jung
CLChang Uk Lee
Chang Uk Lee
BOByoung Hoon Oh
Byoung Hoon Oh
SLSang-Kyu Lee
Sang-Kyu Lee
SCSungku Choi
Sungku Choi
Objective: To investigate the effect of the apolipoprotein E (ApoE) ε4 allele on the efficacy and tolerability of galantamine treatment. Methods: A total of 202 patients with mild to moderate Alzheimer’s disease participated in a 16-week, prospective, multi-center, randomized, double-blind galantamine trial in a Korean population. Patients were assessed at baseline and after 4, 8 and 16 weeks of randomized treatment using the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog/11), the Clinician’s Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the Disability Assessment for Dementia Scale (DAD), the Behavioural Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD) and adverse events. ApoE genotypes were determined for all subjects. Results: Of the 202 subjects, 115 carried at least one ApoE ε4 allele and 87 did not. In both ApoE ε4 carriers and ApoE ε4 noncarriers, significant improvements were detected relative to baseline on ADAS-cog/11, CIBIC-plus, DAD and BEHAVE-AD. ApoE ε4 noncarriers showed better improvement in mean total BEHAVE-AD score and mean psychosis (delusions and hallucinations) subscale score than ApoE ε4 carriers. The incidence of weight loss was significantly higher in ApoE ε4 carriers (n = 11; 9.6%) than in ApoE ε4 noncarriers (n = 1; 1.2%) during this 16-week study, even though 92% of patients who complained of weight loss completed this 16-week trial successfully. Conclusion: ApoE ε4 genotype does not affect galantamine-related improvements in cognition, global rating, function and behavior. Longer prospective studies with larger patient populations are required to confirm these new findings.

1 December 2009 in International Psychogeriatrics
Verified
Journal Article
Open access
PDF file
GSGuk-Hee Suh
Guk-Hee Suh
AWAnders Wimo
Anders Wimo
SGSerge Gauthier
Serge Gauthier
DODaniel O'COnnor
Daniel O'COnnor
MIManabu Ikeda
Manabu Ikeda
BYBong-Min Yang
Bong-Min Yang
Background: Alzheimer's drugs are believed to have limited availability and to be unaffordable in low- and middle-income countries compared to high-income countries. The price, availability and affordability of Alzheimer's drugs have not been reported before. Methods: During 2007 an international survey was conducted in 21 countries in six continents (Argentina, Australia, Brazil, the Dominican Republic, France, India, Japan, Macedonia, Mexico, New Zealand, Nigeria, the Philippines, Portugal, Serbia, South Korea, Switzerland, Taiwan, Thailand, Uganda, the U.K. and the U.S.A.). Prices of Alzheimer's drugs were compared using the affordability index (the total number of units purchasable with one's daily income) derived from purchasing power parity (PPP) converted prices as well as raw prices. Results: Donepezil is available in all 21 countries, whereas the newer drugs are less available. A 5 mg tablet of branded originator donepezil costs just US$0.26 in India and US$0.31 in Mexico, whereas it costs US$6.64 in the U.S.A. Pricing conditions of rivastigmine, galantamine and memantine appear to be similar to that of donepezil. The cheapest branded originators are from India and Mexico. However, in terms of PPP, Alzheimer's drugs in other low- and middle-income countries are much more expensive than in high-income countries. Most people in low- and middle-income countries cannot afford Alzheimer's drugs. Conclusions: Alzheimer's drugs, albeit available, are often unaffordable for those who need them most. It is hoped that equitable differential pricing will be applied to Alzheimer's drugs.

1 January 2008 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
GSGuk-Hee Suh
Guk-Hee Suh
HJHee Yeon Jung
Hee Yeon Jung
CLChang Uk Lee
Chang Uk Lee
SCSungku Choi
Sungku Choi
TGThe Korean Galantamine Study Group
The Korean Galantamine Study Group
Suh GH, et al. J Korean Med Sci. 2008 Feb;23(1):10-17. http://dx.doi.org/10.3346/jkms.2008.23.1.10